Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sunho Biologics's current ratio for the quarter that ended in Jun. 2025 was 6.59.
Sunho Biologics has a current ratio of 6.59. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Sunho Biologics's Current Ratio or its related term are showing as below:
HKSE:02898'
s Current Ratio Range Over the Past 10 Years
Min: 0.22 Med: 6.59 Max: 14.8
Current: 6.59
During the past 3 years, Sunho Biologics's highest Current Ratio was 14.80. The lowest was 0.22. And the median was 6.59.
HKSE:02898's Current Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.825
vs HKSE:02898: 6.59
Sunho Biologics (HKSE:02898) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Sunho Biologics Current Ratio Related Terms
Sunho Biologics Current Ratio Historical Data
* Premium members only.
The historical data trend for Sunho Biologics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02898 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Sunho Biologics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunho Biologics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunho Biologics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Sunho Biologics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunho Biologics (HKSE:02898) has a Current Ratio of 6.59 as of Jun. 2025. This is near median its historical median of 6.59. Over the past decade, Sunho Biologics' Current Ratio has ranged from 0.22 to 14.80.
Is Sunho Biologics' Current Ratio too high?
Sunho Biologics' current Current Ratio of 6.59 is near median its 10-year median of 6.59. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 14.80. The Biotechnology industry median Current Ratio is 3.83. Sunho Biologics' value of 6.59 is 72.3% above this industry median. Overall, Sunho Biologics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sunho Biologics' Current Ratio compare to VRTX and REGN?
Sunho Biologics' Current Ratio of 6.59 can be compared against companies in the Biotechnology industry. The industry median Current Ratio is 3.83. Sunho Biologics' value of 6.59 is 72.3% above this benchmark. Historically, Sunho Biologics' own Current Ratio has ranged from 0.22 to 14.80 over the past decade. While the company's 10-year median is 6.59 vs. the industry median of 3.83, Sunho Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.83, based on 1,406 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunho Biologics's current Current Ratio of 6.59 is 72.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunho Biologics's current Current Ratio is 6.59, which is near median its own 10-year median of 6.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunho Biologics stock overvalued right now?
Sunho Biologics (HKSE:02898) has a current Current Ratio of 6.59. The current Current Ratio is 6.59, which is near median its 10-year median of 6.59 and 72.3% above the Biotechnology industry median of 3.83. Sunho Biologics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Sunho Biologics (HKSE:02898), the current Current Ratio is 6.59 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
11GF Score
Get the complete analysis for HKSE:02898
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02898 has been successfully added to your 
